視神経疾患治療の世界市場規模：治療タイプ別、神経疾患タイプ別、エンドユーザー別、地域範囲別および予測

視神経疾患治療市場の市場規模と予測

視神経疾患治療市場規模は、2024年に36億米ドルと評価され、2026～2032年の予測期間中にCAGR 4.7%で成長し、2032年には57億米ドルに達すると予測されます。

視神経疾患は、視覚情報を眼から脳に伝達する神経線維群である視神経が、炎症（腫脹）によって破壊された状態です。視神経疾患は、片眼の一時的な視力低下と眼球運動時の不快感を特徴とします。視神経疾患の有病率の上昇、座りがちなライフスタイルの採用、糖尿病や血圧・高血圧などの生活習慣病の罹患率の上昇により、視神経疾患治療の世界市場は予測期間中に成長すると予測されています。この調査レポートは、視神経疾患治療の世界市場を包括的に評価しています。

視神経疾患治療の世界市場定義

網膜細胞と視交叉をつなぐ脳神経は視神経として知られています。網膜の視細胞は光を取り込み、視神経を通じて脳に電気インパルスを送る。視力喪失は、病変タイプや部位によって、視神経の機能不全や損傷によって生じる可能性があります。片目または両眼に視力疾患が生じる可能性があります。電気信号は、網膜の視細胞から視神経を介して脳の視覚野に送られます。

視神経やその経路に損傷があれば、目に永久的な損傷を与え、視力低下を引き起こす可能性があります。視神経を損傷する可能性のある最も頻度の高い疾患のひとつに、視神経疾患があります。視神経は、それを覆っている保護膜であるミエリンの損傷や喪失によって炎症を起こします。研究者によれば、視神経疾患は炎症とミエリンの破壊によって引き起こされる可能性があるといいます。2本の神経は、視交叉で収束するという重要な役割を担っています。

視神経が真っ二つに分かれると、左右の神経線維の半分ずつが反対側に渡る。傷害と神経の保護被覆の除去の両方が神経の炎症を引き起こします。緑内障、視神経疾患、視神経萎縮、視神経円板ドルーゼン（ODD）などが視神経疾患です。治療の選択肢には、コルチコステロイド、免疫グロブリン静注（IVIG）/血漿交換、ビタミンB12注射、手術などがあり、特定された疾患の程度や種類によって異なります。

視神経疾患治療の世界市場概要

WHOによると、2019年には世界で22億人が視覚疾患または失明を経験しました。このうち、白内障、未矯正屈折異常、緑内障、角膜混濁などが視力疾患の主要原因です。眼球内の液圧が上昇し、視神経疾患を悪化させる重大な要因の一つが緑内障です。緑内障は、感染症や化学品による眼疾患などによっても発症しますが、遺伝することが多い病気です。早期発見・早期治療には、点眼薬、内服薬、レーザー治療などの方法があります。

多発性硬化症（MS）は、免疫系が体の健康な細胞を攻撃する自己免疫疾患であり、視神経疾患の主要原因です。免疫力の低下により、MSは高齢化社会に多く見られるようになり、糖尿病、喫煙、感染症などによっても発症します。座りがちな生活、悪い食生活、運動不足などにより、糖尿病、血圧、高血圧などの生活習慣病が増加しており、MSが眼神経炎を引き起こす可能性がさらに高くなっています。その結果、この病気に対する治療が必要な人の割合が増加しています。視神経疾患の治療には一般的にステロイドが使用され、症状の進行を防ぎます。

視神経の病気には決定的な治療法はありませんが、薬剤療法や投薬、手術による合併症を避けるため、予防と早期発見が重視されています。高齢者の増加と、症状の悪化を食い止めるための早期診断の必要性に対する意識の高まりが、視神経疾患の治療や手術の需要を高め、それらの治療市場の成長を後押ししています。しかし、緑内障のような視神経疾患の治療の使用に伴う潜在的な副作用（目の色の変化、くぼみ、かゆみなど）により、市場の拡大は妨げられています。

目次

第1章 世界の視神経疾患治療市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• 二次調査
• 一次調査
• 専門家のアドバイス
• 品質チェック
• 最終レビュー
• データの三角測量
• ボトムアップアプローチ
• トップダウンアプローチ
• 調査の流れ
• データソース

第3章 エグゼクティブサマリー

• 概要
• 絶対的収益機会
• 市場の魅力
• 将来の市場機会

第4章 視神経疾患治療の世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 視神経疾患治療の世界市場：治療タイプ別

• 概要
• 点眼薬
• ステロイド
• 免疫グロブリン静注/血漿交換
• ビタミンB12注射
• 外科手術

第6章 視神経疾患治療の世界市場：神経疾患タイプ別

• 概要
• 緑内障
• 視神経疾患
• その他

第7章 視神経疾患治療の世界市場：エンドユーザー別

• 概要
• 病院
• 眼科クリニック
• 外来手術センター

第8章 視神経疾患治療の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界の視神経疾患治療市場の競合情勢

• 概要
• 各社の市場ランキング
• 主要開発戦略
• 企業の地域別フットプリント
• 企業の産業別フットプリント
• ACEマトリックス

第10章 企業プロファイル

• Bionure Farma S.L.
• Teva Pharmaceutical Industries
• Santen Pharmaceutical
• Novartis AG
• Pfizer
• Allergan
• Aerie Pharmaceuticals
• Mallinckrodt Pharmaceuticals
• Merck Sharp & Dohme Corp
• Bausch Health Companies

第11章 主要開発

• 製品の上市/開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第12章 付録

• 関連調査

Optic Nerve Disorders Treatment Market Size And Forecast

Optic Nerve Disorders Treatment Market size was valued at USD 3.6 Billion in 2024 and is projected to reach USD 5.7 Billion by 2032, growing at a CAGR of 4.7% during the forecast period 2026-2032.

Optic neuritis is a condition in which the optic nerve, a group of nerve fibers that transmits visual information from the eye to the brain, is destroyed by inflammation (swelling). Optic neuritis is characterized by temporary vision loss in one eye and discomfort with eye movement. Due to the rising prevalence of optic illnesses, the adoption of a sedentary lifestyle, and the rising incidence of lifestyle diseases like diabetes, Blood Pressure & Hypertension, the global market for treatments for optic nerve disorders is anticipated to grow over the course of the forecasted period. The market is comprehensively evaluated in the study on the global market for treating optic nerve disorders.

Global Optic Nerve Disorders Treatment Market Definition

The cranial nerves that connect the retinal cells to the optic chiasm are known as the optic nerves. The retina's photoreceptor cells take in light and send electric impulses to the brain through the optic nerves. Loss of vision could result from malfunction or damage to the optic nerves, depending on the type and location of the lesion. One or both eyes could experience vision impairment. Electrical signals are sent from retinal photoreceptor cells via the optic nerve to the brain's visual cortex.

Any damage to the optic nerve or its pathways has the potential to permanently harm the eyes and cause vision loss. One of the most frequent conditions that might harm the optic nerve is optic neuritis. The optic nerve is inflamed as a result of damage to or loss of myelin, the protective covering that covers it. Optic neuritis may be brought on by inflammation and myelin breakdown, according to researchers. The two nerves perform an essential task and converge at the optic chiasm.

Half of each side's nerve fibers cross over to the other side as the optic nerve splits in half. Injury and the removal of the nerve's protective covering both cause inflammation of the nerve. Glaucoma, optic neuritis, atrophy of the optic nerve, and optic disc drusen (ODD), among other conditions, are optic nerve disorders. Therapy options include corticosteroids, intravenous immune globulin (IVIG)/plasma exchange, vitamin B12 injection, and surgery, among others, depending on the degree and kind of disease identified.

Global Optic Nerve Disorders Treatment Market Overview

In 2019, 2.2 billion individuals worldwide experienced visual impairment or blindness, according to WHO. Out of these, cataracts, uncorrected refractive errors, glaucoma, corneal opacification, etc. are the main causes of vision impairment. One significant factor that contributes to the increase in fluid pressure in the eye, which worsens optic nerve damage, is glaucoma. It is frequently inherited by people, although it can also be brought on by an infection, an eye injury from chemicals, etc. Early detection and treatment options include eye drops, oral drugs, and operations like laser therapy.

Multiple sclerosis (MS), an autoimmune condition associated with the immune system attacking the body's healthy cells, is the primary cause of optic neuritis. Due to lowered immunity, MS is becoming more common in the aging population, while it can also be brought on by diabetes, smoking, infections, etc. Due to sedentary lifestyles, bad diets, lack of physical activity, etc., there is an increase in lifestyle disorders like diabetes, blood pressure, hypertension, etc., which further increases the likelihood that MS may cause ocular neuritis. The percentage of persons who need therapy for the disease is increasing as a result. Steroids are typically used to treat optic neuritis in order to prevent the condition's future progression.

Although there is no definitive cure for optic nerve illnesses, there is a lot of emphasis on preventing them and finding them early to avoid complications from medication, medications, and surgery. The increase in the elderly population and the growing awareness of the need for early diagnosis to stop the condition from getting worse has increased the demand for drugs and surgeries for treating optic nerve disorders, which has fueled the growth of the market for those treatments. However, the market's expansion is being hampered by potential side effects associated with the usage of medications for the treatment of optic nerve disorders like glaucoma, such as changing eye color, sunken eyes, itching, etc.

Global Optic Nerve Disorders Treatment Market Segmentation Analysis

The Global Optic Nerve Disorders Treatment Market is segmented on the basis of Type of Treatment, Type of Nerve Disorder, End User, And Geography.

Optic Nerve Disorders Treatment Market, By Type of Treatment

• Eye Drops
• Steroids
• Intravenous immune Globulin/ Plasma Exchange
• Vitamin B12 injection
• Surgery

Based on Type of Treatment, The market is segmented into Eye Drops, Steroids, Intravenous immune globulin (IVIG)/Plasma Exchange, Vitamin B12 injection, and Surgery. Due to their simplicity of use, quick start of the action, and increased efficacy, eye drops are predicted to experience the largest growth during the estimated period.

• Numerous common disorders are treated using eye drops. They can be used for tired, itchy eyes brought on by allergies. They might be recommended for bacterial or viral infections as well as other disorders like glaucoma. The entire therapeutic benefit of the drug might not be experienced when eye drops are not properly administered or used.

Optic Nerve Disorders Treatment Market, By Type of Nerve Disorder

• Glaucoma
• Optic neuritis
• Others

Based on Type of Nerve Disorder, The market is segmented into Glaucoma, Optic neuritis, and Others. Due to a lack of knowledge about glaucoma and the rising elderly population, glaucoma is anticipated to rise the most during the anticipated time. due to an increase in open-angle glaucoma prevalence. Additionally, it is projected that an increase in the number of medications approved for the treatment of open-angle glaucoma will spur market expansion.

• Additionally, the market for treatments for optic neuritis is anticipated to increase at the quickest rate throughout the anticipated period. This is ascribed to the rise in optic neuritis prevalence, the availability of reimbursement policies, and rising public awareness of multiple sclerosis driving the market expansion.

Optic Nerve Disorders Treatment Market, By End User

• Hospitals
• Ophthalmology Clinics
• Ambulatory Surgical Centers

Based on End User, The market is segmented into Hospitals, Ophthalmology Clinics, and Ambulatory Surgical Centers. Due to the increased prevalence of optical disorders, accessibility to cutting-edge technology, and well-established healthcare infrastructure, the hospital segment is anticipated to grow the most throughout the anticipated period.

• The availability of enhanced healthcare infrastructure, the rise in unmet healthcare needs, the rise in the prevalence of eye disease, and the spike in demand for medications to treat optic nerve disorders all point to high promise in unexplored, emerging markets. Additionally, the desire for better healthcare services, large government investments in enhancing the infrastructure for healthcare, and the growth of the medical tourism sector in emerging nations are all contributing to the significant growth of the healthcare sector in emerging economies.

Optic Nerve Disorders Treatment Market, By Geography

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• Latin America

Based on Geography, The Global Optic Nerve Disorders Treatment Market is classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. Due to its high illness prevalence, accessibility of reimbursement policies, and rising public awareness of multiple sclerosis and optic neuritis, the Asia Pacific area is anticipated to rise more than any other region throughout the forecasted period.

• The market has grown in this area due to the presence of pharmaceutical companies there as well as the increasing purchasing power of populous countries like China and India. The market is expanding due to the aging population as well as the rising prevalence of diseases affecting the optic nerve, including glaucoma and optic neuritis.

Key Players

The "Global Optic Nerve Disorders Treatment Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as Bionure Farma S.L., Teva Pharmaceutical Industries Ltd, Santen Pharmaceutical Co. Ltd., Novartis AG, Pfizer Inc., Allergan plc., Aerie Pharmaceuticals Inc, Mallinckrodt Pharmaceuticals, Merck Sharp & Dohme Corp, and Bausch Health Companies, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

Key Developments

• In February 2022, The results of a recent trial conducted by Horizon Therapeutics plc (Nasdaq: HZNP) showed that UPLIZNA medication effectively reduced the intensity of attacks in NMOSD patients.
• Ace Matrix Analysis
• The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
• Market Attractiveness
• The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Optic Nerve Disorders Treatment Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
• Porter's Five Forces
• The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. The porter's five forces model can be used to assess the competitive landscape in Global Optic Nerve Disorders Treatment Market gauge the attractiveness of a certain sector, and assess investment possibilities.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 2.1 Data mining
• 2.2 Secondary research
• 2.3 Primary research
• 2.4 Subject matter expert advice
• 2.5 Quality check
• 2.6 Final review
• 2.7 Data triangulation
• 2.8 Bottom-up approach
• 2.9 Top-down approach
• 2.10 Research flow
• 2.11 Data sources

3 EXECUTIVE SUMMARY

• 3.1 Overview
• 3.2 Absolute $ Opportunity
• 3.3 Market attractiveness
• 3.4 Future Market Opportunities

4 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY TYPE OF TREATMENT

• 5.1 Overview
• 5.2 Eye Drops
• 5.3 Steroids
• 5.4 Intravenous immune Globulin/ Plasma Exchange
• 5.5 Vitamin B12 injection
• 5.6 Surgery

6 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY TYPE OF NREVE DISORDER

• 6.1 Overview
• 6.2 Glaucoma
• 6.3 Optic neuritis
• 6.4 Others

7 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY END USER

• 7.1 Overview
• 7.2 Hospitals
• 7.3 Ophthalmology Clinics
• 7.4 Ambulatory Surgical Centers

8 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies
• 9.4 Company Regional Footprint
• 9.5 Company Industry Footprint
• 9.6 ACE Matrix

10 COMPANY PROFILES

• 10.1 Bionure Farma S.L.
  • 10.1.1 Company Overview
  • 10.1.2 Company Insights
  • 10.1.3 Business Breakdown
  • 10.1.4 Product Benchmarking
  • 10.1.5 Key Developments
  • 10.1.6 Winning Imperatives
  • 10.1.7 Current Focus & Strategies
  • 10.1.8 Threat from Competition
  • 10.1.9 SWOT Analysis
• 10.2 Teva Pharmaceutical Industries
  • 10.2.1 Company Overview
  • 10.2.2 Company Insights
  • 10.2.3 Business Breakdown
  • 10.2.4 Product Benchmarking
  • 10.2.5 Key Developments
  • 10.2.6 Winning Imperatives
  • 10.2.7 Current Focus & Strategies
  • 10.2.8 Threat from Competition
  • 10.2.9 SWOT Analysis
• 10.3 Santen Pharmaceutical
  • 10.3.1 Company Overview
  • 10.3.2 Company Insights
  • 10.3.3 Business Breakdown
  • 10.3.4 Product Benchmarking
  • 10.3.5 Key Developments
  • 10.3.6 Winning Imperatives
  • 10.3.7 Current Focus & Strategies
  • 10.3.8 Threat from Competition
  • 10.3.9 SWOT Analysis
• 10.4 Novartis AG
  • 10.4.1 Company Overview
  • 10.4.2 Company Insights
  • 10.4.3 Business Breakdown
  • 10.4.4 Product Benchmarking
  • 10.4.5 Key Developments
  • 10.4.6 Winning Imperatives
  • 10.4.7 Current Focus & Strategies
  • 10.4.8 Threat from Competition
  • 10.4.9 SWOT Analysis
• 10.5 Pfizer
  • 10.5.1 Company Overview
  • 10.5.2 Company Insights
  • 10.5.3 Business Breakdown
  • 10.5.4 Product Benchmarking
  • 10.5.5 Key Developments
  • 10.5.6 Winning Imperatives
  • 10.5.7 Current Focus & Strategies
  • 10.5.8 Threat from Competition
  • 10.5.9 SWOT Analysis
• 10.6 Allergan
  • 10.6.1 Company Overview
  • 10.6.2 Company Insights
  • 10.6.3 Business Breakdown
  • 10.6.4 Product Benchmarking
  • 10.6.5 Key Developments
  • 10.6.6 Winning Imperatives
  • 10.6.7 Current Focus & Strategies
  • 10.6.8 Threat from Competition
  • 10.6.9 SWOT Analysis
• 10.7 Aerie Pharmaceuticals
  • 10.7.1 Company Overview
  • 10.7.2 Company Insights
  • 10.7.3 Business Breakdown
  • 10.7.4 Product Benchmarking
  • 10.7.5 Key Developments
  • 10.7.6 Winning Imperatives
  • 10.7.7 Current Focus & Strategies
  • 10.7.8 Threat from Competition
  • 10.7.9 SWOT Analysis
• 10.8 Mallinckrodt Pharmaceuticals
  • 10.8.1 Company Overview
  • 10.8.2 Company Insights
  • 10.8.3 Business Breakdown
  • 10.8.4 Product Benchmarking
  • 10.8.5 Key Developments
  • 10.8.6 Winning Imperatives
  • 10.8.7 Current Focus & Strategies
  • 10.8.8 Threat from Competition
  • 10.8.9 SWOT Analysis
• 10.9 Merck Sharp & Dohme Corp
  • 10.9.1 Company Overview
  • 10.9.2 Company Insights
  • 10.9.3 Business Breakdown
  • 10.9.4 Product Benchmarking
  • 10.9.5 Key Developments
  • 10.9.6 Winning Imperatives
  • 10.9.7 Current Focus & Strategies
  • 10.9.8 Threat from Competition
  • 10.9.9 SWOT Analysis
• 10.10 Bausch Health Companies
  • 10.10.1 Company Overview
  • 10.10.2 Company Insights
  • 10.10.3 Business Breakdown
  • 10.10.4 Product Benchmarking
  • 10.10.5 Key Developments
  • 10.10.6 Winning Imperatives
  • 10.10.7 Current Focus & Strategies
  • 10.10.8 Threat from Competition
  • 10.10.9 SWOT Analysis

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 APPENDIX

• 12.1 Related Research